A deimmunized and pharmacologically optimized Toll-like receptor 5 agonist for therapeutic applications
Mett et al. describe development of GP532, a substantially deimmunized derivative of Toll-like receptor 5 (TLR5) agonist entolimod. GP532 has mutations eliminating key B- and T-cell epitopes and an inflammasome-activating domain yet remains a potent NF-κB activator with biological effects similar to...
Main Authors: | Vadim Mett, Oleg V. Kurnasov, Ivan A. Bespalov, Ivan Molodtsov, Craig M. Brackett, Lyudmila G. Burdelya, Andrei A. Purmal, Anatoli S. Gleiberman, Ilia A. Toshkov, Catherine A. Burkhart, Yakov N. Kogan, Ekaterina L. Andrianova, Andrei V. Gudkov, Andrei L. Osterman |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Publishing Group
2021-04-01
|
Series: | Communications Biology |
Online Access: | https://doi.org/10.1038/s42003-021-01978-6 |
Similar Items
-
TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects.
by: Gary J Haderski, et al.
Published: (2020-01-01) -
The Toll-Like Receptor 5 Agonist Entolimod Mitigates Lethal Acute Radiation Syndrome in Non-Human Primates.
by: Vadim I Krivokrysenko, et al.
Published: (2015-01-01) -
Resistance of bone marrow stroma to genotoxic preconditioning is determined by p53
by: Natalia Fedtsova, et al.
Published: (2021-05-01) -
Design and Engineering of Deimmunized Vaccinia Viral Vectors
by: Kevin Song, et al.
Published: (2020-11-01) -
Optimization algorithms for functional deimmunization of therapeutic proteins
by: Griswold Karl E, et al.
Published: (2010-04-01)